 |
| Recombinant Erythropoietin Market |
Recombinant Erythropoietin is a protein hormone that stimulates red blood cell production. It is used to treat anemia caused by chronic kidney disease and certain cancers. Recombinant Erythropoietin drugs help increase red blood cell levels and reduce the need for blood transfusions.
The global
Recombinant Erythropoietin Market is estimated to be valued at US$ 18 billion in 2024 and is expected
to exhibit a CAGR of 3.4% over the
forecast period 2024 to 2031, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
Advancement in recombinant technology has been a major trend propelling the
growth of the Recombinant Erythropoietin market. Recombinant DNA technology has
enabled mass production of erythropoietin in a purified form and with
consistent quality, fulfilling the increasing demand. Earlier, erythropoietin
was extracted from urine which had low yield and supply issues. With
advancement, mammalian cell lines like Chinese Hamster Ovary (CHO) cells are
being used for commercial production of recombinant EPO. This process ensures
higher yield, safety, low cost of goods and consistent supply. Rising adoption
of recombinant EPO drugs across the world due to their effectiveness over
urine-extracted versions has been the key factor fueling the market growth over
the forecast period.
Segment Analysis
The global recombinant erythropoietin (EPO) market is segmented based on
application into anemia, AIDS treatment, kidney disorders, cancer treatment and
others. The kidney disorders segment held over half of the total market share
in 2024 driven by rising number of patients suffering from chronic kidney
diseases globally. The cancer treatment segment is expected to witness
lucrative growth owing to increasing incidences of cancer and immense use of
EPO for reducing cancer treatment-related anemia.
Key Takeaways
The global Recombinant
Erythropoietin Market Growth is estimated to be valued at US$ 18
billion in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast
period 2024 to 2031.
Regional analysis: North America accounted for the largest share of the global
recombinant EPO market in 2024 due to increasing focus on research and
development activities pertaining to biologics. Asia Pacific is anticipated to
witness robust growth due to various developments in the healthcare sector,
rising disposable incomes and growing awareness regarding anemia treatments.
Key players: Key players operating in the recombinant EPO market are Amgen
Inc., Pfizer Inc., Johnson & Johnson, Dr. Reddy's Laboratories Ltd.,
Biocon, Intas Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd. Amgen
Inc. held a significant market share owing to its diverse EPO portfolio and
widespread distribution network across major markets.
For more insights, read- https://www.ukwebwire.com/recombinant-erythropoietin-market-trends-size-and-share-analysis/
For more details on the report, Read- https://dailynewsmotion.weebly.com/report-blog/plant-based-meat-market-is-estimated-to-witness-high-growth-owing-to-opportunity
0 Comments